Skip Navigation

Phase II, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin ABBV-399 in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

Brief Summary

Lung Cancers

Study Type:

II Identifier:

Study #:

Start Date:
Jan 10, 2021

Full Details and Eligibility at

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below. ID: NCT03539536

View Complete Trial Details & Eligibility at